Annals of Surgical Oncology

, Volume 21, Issue 2, pp 426–433

Negative Parafibromin Staining Predicts Malignant Behavior in Atypical Parathyroid Adenomas

  • Schelto Kruijff
  • Stan B. Sidhu
  • Mark S. Sywak
  • Anthony J. Gill
  • Leigh W. Delbridge
Endocrine Tumors

DOI: 10.1245/s10434-013-3288-8

Cite this article as:
Kruijff, S., Sidhu, S.B., Sywak, M.S. et al. Ann Surg Oncol (2014) 21: 426. doi:10.1245/s10434-013-3288-8

Abstract

Background

The histopathological criteria for carcinoma proposed by the World Health Organization (WHO) are imperfect predictors of the malignant potential of parathyroid tumors. Negative parafibromin (PF) and positive protein gene product 9.5 (PGP9.5) staining are markers of CDC73 mutation and occur commonly in carcinoma but rarely in adenomas. We investigated whether PF and PGP9.5 staining could be used to predict the behavior of atypical parathyroid adenomas—tumors with atypical features that do not fulfill WHO criteria for malignancy.

Methods

Long-term outcomes were compared across four groups: group A, WHO-positive criteria/PF-negative staining; group B, WHO+/PF+, group C; WHO/PF; and group D, WHO/PF+.

Results

Eighty-one patients were included in the period 1999–2012: group A (n = 13), group B (n = 14), group C (n = 21), and group D (n = 33). Mortality and recurrence rates, respectively, for group A were 15 and 38 %, for group B 7 and 36 %, for group C 0 and 10 %, and for group D 0 and 0 %. The PGP9.5+ ratios for groups A to D were 85, 78, 71, and 12 %, further informing prognosis. Five-year disease-free survival for groups A to D were 55, 80, 78, and 100 %, respectively. Tumor recurrence was significantly associated with PF (p = 0.048) and PGP9.5 (p = 0.003) staining.

Conclusions

Although WHO criteria are essential to differentiate parathyroid carcinoma from benign tumors, the presence of negative PF staining in an atypical adenoma predicts outcome better, whereas PF-positive atypical adenomas do not recur and can be considered benign. PF-negative atypical adenomas have a low but real recurrence risk and should be considered tumors of low malignant potential.

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Schelto Kruijff
    • 1
  • Stan B. Sidhu
    • 1
  • Mark S. Sywak
    • 1
  • Anthony J. Gill
    • 2
    • 3
  • Leigh W. Delbridge
    • 1
  1. 1.Endocrine Surgical UnitUniversity of SydneySydneyAustralia
  2. 2.Department of PathologyRoyal North Shore HospitalSt. LeonardsAustralia
  3. 3.Department of PathologyUniversity of SydneySydneyAustralia

Personalised recommendations